AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hypotension - Pipeline Review, H1 2019 - ResearchAndMarkets.com

April 16, 2019

DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Hypotension - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hypotension - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 1, 2, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Jan 29, 2019: Theravance doses first patient in Phase II trial of ampreloxetine
  • Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
  • May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
  • Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
  • Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
  • Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
  • Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
  • May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
  • Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
  • Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
  • Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
  • Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
  • Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
  • Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
  • Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study In Neurogenic Orthostatic Hypotension

Companies Mentioned

  • Cerecor Inc.
  • Handa Pharmaceuticals LLC
  • La Jolla Pharmaceutical Company
  • Theravance Biopharma Inc.
  • TrioxBio Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/91um1g

View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005530/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/16/2019 07:53 AM/DISC: 04/16/2019 07:53 AM

http://www.businesswire.com/news/home/20190416005530/en